Britain and America have agreed to a landmark bilateral deal that will guarantee no duties on British pharmaceutical exports entering the American market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to raise funding on medicines through the public health system. This commitment guarantees that tariffs on these key goods will remain at zero for a period of 36 months.
This development comes after earlier statements to dramatically increase import taxes on patented pharmaceutical products, with potential rates floated up to 100%.
"This agreement between the United Kingdom strengthens the international landscape for new treatments and establishes long-overdue fairness to American-British medicine commerce," an announcement noted.
Trade Impact
Drugs are one of the the United Kingdom's largest goods shipped to the America, which is clearly the largest buyer for leading companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months to the end of September, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This value accounted for 17.4% of total UK exports in that span.
"This deal secures employment, stimulates capital expenditure and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Detailed NHS Changes
The agreement entails several specific pledges from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to double total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Last year, refunds exceeded 20%.
Industry Background
This agreement comes amid a protracted row between the drug companies and the UK government over medicine costs and regulatory access.
This friction were exacerbated by claims that American patients were paying a premium for the identical medicines than patients in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar expansions have been directed toward US facilities.
The Science Minister stated that the NHS must invest a greater share on treatments, noting that its spending on drugs had shrunk as a share of its overall budget over the previous ten-year period.
